Description
ADCC-enhanced Andecaliximab is a non-fucosylated anti-MMP9 therapeutic biobetter antibody.
Indication
Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced MMP9 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Matrix Metallopeptidase 9
Background
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The enzyme encoded by this gene degrades type IV and V collagens. Studies in rhesus monkeys suggest that the enzyme is involved in IL-8-induced mobilization of hematopoietic progenitor cells from bone marrow, and murine studies suggest a role in tumor-associated tissue remodeling. [provided by RefSeq, Jul 2008]
Alternative Names
Matrix metallopeptidase 9; gelatinase B
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with MMP9 include Metaphyseal Anadysplasia 2 and Metaphyseal Anadysplasia.
Related Pathways
Its related pathways are Regulation of Wnt-mediated beta catenin signaling and target gene transcription and Transcriptional misregulation in cancer.
Function
It may play an important role in the local proteolysis of extracellular matrix and leukocyte migration. Can play a role in the resorption of bone osteoclasts. Cleaves kisses on the Gly-|-leu key. Cleavage type IV and V collagen into c-terminal 3/4 large fragments and shorter n-terminal 1/4 fragments. Degrades fibronectin, but does not degrade laminin or pz peptide.
Field of research
Brain Injury IHC Study antibody
Post-translational modifications
Processing of the precursor yields different active forms of 64, 67 and 82 kDa. Sequentially processing by MMP3 yields the 82 kDa matrix metalloproteinase-9. N- and O-glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Andecaliximab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to MMP9. Andecaliximab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors.
Indication
Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors
